Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 73Gastrointestinal 57Genitourinary 22Breast 12Gynecologic 11Head & Neck 6Tumor-Agnostic 5Sarcoma 5Other hematologic neoplasm 2Dermatologic 2CNS 2Other solid neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 172Rituximab 157Specimen Handling 116Biopsy 93Magnetic Resonance Spectroscopy 90Vincristine 89Doxorubicin 83Prednisone 81fludarabine 70venetoclax 67obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 46acalabrutinib 43Etoposide 41blinatumomab 40CT-P10 39Bendamustine Hydrochloride 37fludarabine phosphate 33Gemcitabine 33prednylidene 32Calcium Dobesilate 32deltacortene 31zanubrutinib 30pembrolizumab 29glofitamab 28Nivolumab 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
durvalumab × Lymphoid × 90 days × Clear all
NCT05388006 2026-03-25

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

Phase 2 Recruiting
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡